TCRT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
-100.0%
3.0K
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
3.0K
0
0
Operating Expenses
952.0K
-5.9%
1.0M
+11.2%
910.0K
-23.3%
1.2M
+14.2%
1.0M
R&D
388.0K
-9.1%
427.0K
+18.3%
361.0K
-23.0%
469.0K
+153.5%
185.0K
SG&A
564.0K
-3.6%
585.0K
+6.6%
549.0K
-23.5%
718.0K
-15.9%
854.0K
Operating Income
-952000
+5.9%
-1012000
-11.6%
-907000
+23.6%
-1187000
-14.2%
-1039000
EBITDA
-943000
+6.1%
-1004000
-11.6%
-900000
+24.2%
-1187000
-14.2%
-1039000
Net Income
-952000
+5.4%
-1006000
-12.7%
-893000
+23.0%
-1159000
-10.3%
-1051000
EPS (Basic)
$-0.41
+30.5%
$-0.59
-37.2%
$-0.43
+21.8%
$-0.55
+12.7%
$-0.63
EPS (Diluted)
$-0.41
+30.5%
$-0.59
-37.2%
$-0.43
+21.8%
$-0.55
+12.7%
$-0.63
Shares (Diluted)
2.4M
+24.8%
1.9M
-16.5%
2.3M
+6.9%
2.2M
+30.2%
1.7M
Alaunos Therapeutics (TCRT) โ€” Financials